Foon K A, Gale R P, Todd R F
Semin Hematol. 1986 Oct;23(4):257-83.
Important insights into leukocyte differentiation and the cellular origins of leukemia have been gained through the use of monoclonal antibodies that define cell surface antigens and molecular probes that identify immunoglobulin and T cell receptor genes. Results of these studies have been combined with markers such as surface membrane and cytoplasmic immunoglobulin on B lymphocytes, sheep erythrocyte receptors on T lymphocytes, and cytochemical stains. Using all of the above markers, it is now clear that acute lymphoblastic leukemia (ALL) is heterogeneous. Although monoclonal antibodies are useful in distinguishing acute myeloid from acute lymphoid leukemias, they have less certain usefulness in the subclassification of acute myelogenous leukemia (AML). Attempts to subclassify AML by differentiation-associated antigens rather than by the French-American-British (FAB) classification are underway in order to document the potential prognostic usefulness of surface markers.
通过使用定义细胞表面抗原的单克隆抗体和识别免疫球蛋白及T细胞受体基因的分子探针,人们对白细胞分化和白血病的细胞起源有了重要认识。这些研究结果已与诸如B淋巴细胞上的表面膜和细胞质免疫球蛋白、T淋巴细胞上的绵羊红细胞受体以及细胞化学染色等标志物相结合。利用上述所有标志物,现在很清楚急性淋巴细胞白血病(ALL)是异质性的。虽然单克隆抗体有助于区分急性髓细胞白血病和急性淋巴细胞白血病,但它们在急性髓细胞白血病(AML)的亚分类中的作用尚不确定。目前正在尝试通过与分化相关的抗原而非法国-美国-英国(FAB)分类对AML进行亚分类,以便记录表面标志物的潜在预后价值。